论文部分内容阅读
研究肾细胞癌血管内皮生长因子（ＶＥＧＦ）的表达及其与肿瘤转移、分期、病理类型及预后的关系。采用抗ＶＥＧＦ的多克隆抗体免疫组织化学技术染色（ＬｓＡＢ法）研究６１例肾癌组织切片。结果显示：４５９％（２８／６１）的肾癌ＶＥＧＦ表达阳性，淋巴结和（或）血行转移的ＶＥＧＦ表达率（７７８％）明显高于非转移者（３２６％，Ｐ＜００１）；阳性表达者五年生存率（２９１％）明显低于阴性表达者（８４６％，Ｐ＜００１）；Ⅰ、Ⅱ期阳性表达低于Ⅲ、Ⅳ期（Ｐ＜００５）；但与性别、年龄及肿瘤的病理类型无关。ＶＥＧＦ除在癌细胞胞浆和胞膜表达外，尚表达于肿瘤基质血管和邻近肿瘤的正常肾小管胞浆、肾小球和血管内皮及血管平滑肌胞膜。认为ＶＥＧＦ除由肿瘤细胞合成外，可能尚表达于邻近肿瘤的正常肾小管胞浆，ＶＥＧＦ表达有助于肾癌预后判断及指导治疗，ＶＥＧＦ可能是肿瘤血管的良好标记物，设法抑制ＶＥＧＦ可望成为肾癌治疗的有效方法。
To study the expression of vascular endothelial growth factor (VEGF) in renal cell carcinoma and its relationship with tumor metastasis, staging, pathological type and prognosis. Immunohistochemical staining (LsAB method) of polyclonal anti-VEGF antibody was used to study 61 cases of renal cell carcinoma. The results showed that VEGF expression was positive in 45.9% (28/61) of patients with renal cell carcinoma, and the positive rate of VEGF (778%) in lymph node and / or hematogenous metastasis was significantly higher than that in non-metastatic lymph node (326%, P < 001). The five-year survival rate (291%) in positive expression was significantly lower than that in negative expression (846%, P <001). The positive expression in stage Ⅰ and Ⅱ was lower than that in stage Ⅲ and Ⅳ P <0 05); but with gender, age and pathological type of tumor has nothing to do. In addition to the expression of VEGF in cytoplasm and cytoplasm of cancer cells, VEGF is still expressed in the normal tubular cells, glomerular and vascular endothelium and vascular smooth muscle cells of tumor stroma vessels and adjacent tumors. It is suggested that VEGF may be expressed in adjacent normal nephric tubule cytoplasm of tumor besides VEGF synthesized by tumor cells. VEGF expression is helpful to judge prognosis of renal cell carcinoma and guide therapy. VEGF may be a good marker of tumor blood vessel, As an effective treatment of renal cell carcinoma.